

References

I-34

1. Culos KA, Cuellar S. Novel targets in the treatment of advanced melanoma: new first-line treatment options. *Ann Pharmacother*. 2013 Apr;47(4):519-26.
2. Scarpati, G , Fusciello C, Perri F, et al. Ipilimumab in the treatment of metastatic melanoma: Management of adverse events. *Onco Targets Ther*. 2014;7:203-209.
3. Chmielowski B. Ipilimumab: A first-in-class T-cell potentiator for metastatic melanoma. *Journal of Skin Cancer*. 2013. Published online Apr 21, 2013.
4. Konstantinou M, Dutriaux C, Gaudy-Marqueste C, et al. Ipilimumab in melanoma patients with brain metastasis: A retrospective multicentre evaluation of thirty-eight patients. *Acta Derm Venereol*. 2013. Epub ahead of print Jul 4, 2013.
5. Feldmann G, Brossart P, Zipfel M, and von Lilienfeld-Toal M. Mixed response to ipilimumab in a melanoma patient with brain metastases: Case report and review of the literature. *Case Rep Oncol*. 2013;6(1):229–235.
6. Khoja, L Atenafu EG, Ye Q, et al. Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. *Oncology Letters*. 2016;1581-1585.
7. Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, et al. Two-year overall survival rates from a randomized phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma. *Lancet Oncol*. 2016;17(11):1558-1568.
8. Antonia SJ, Lopez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. *Lancet Oncol*. 2016;883-895.
9. National Comprehensive Cancer Network® (NCCN) 2018. Drugs and Biologics Compendium. Ipilimumab.
10. Yervoy® (ipilimumab) [package insert]. Princeton, NJ. Bristol-Myers Squibb. 2015.
11. Micromedex®Solutions Compendia. 2018. Ipilimumab.
12. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. Ipilimumab. 2018.
13. Grosso JF and Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. *Cancer Immunity*. 2013;13:1-14.
14. Queriolo P, Spagnolo F, Ascierto PA, Simeone E, Marchetti P, Scoppola A, et al. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. *J Neurooncol*.

2014;118:109-116.

15. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. *J Clin Oncol*. 2015;33(17):1889-1896.
16. Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, et al. Pooled analysis safety profiles of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. *J Clin Oncol*. 2017;35(34):3815-3826.